|
|
Article: PURE Bioscience Announces the Cleveland Clinic Has Taken an Equity Stake in FTA Therapeutics.
- Article from:
- Business Wire
- Article date:
- July 30, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FTA Therapeutics, PURE's Pharmaceutical Development Partner, Names Board of Directors
SAN DIEGO -- PURE Bioscience (NASDAQ: PURE) today announced that Cleveland Clinic has been issued an equity stake in FTA Therapeutics LLC, PURE's pharmaceutical development partner for its patented silver dihydrogen citrate (SDC) antimicrobial.
Dr. Frank Papay, co-founder of FTA, commented, "After a lengthy and thorough evaluation process, we are proud to announce that one of the top hospitals in the world, Cleveland Clinic which has one of the largest biomedical engineering department in the US, has agreed to work with FTA as part of FTA's development projects with ...